In Table 1, we outline T cell lymphomas with aberrant STAT3 signaling and highlight the relevant literature demonstrating that this pathway is frequently dysregulated in these malignancies and as such represents a promising therapeutic target. This evidence concerns the gene STAT3 and T-cell non-Hodgkin lymphoma.